Pancreatic Cancer Research

ResearcherRutgers HealthActive in the last 2 years

Chen Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0003-0430-6146; OpenAlex author ID A5100322216. Sources: OpenAlex.

Their work

Papers
24 (first author 1, last author 4)
Trials
0
Grants
0
Labs led
2
Collaborators
61
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: 4 papers · 2015: 4 papers · 2016: 3 papers · 2017: 1 paper · 2018: 1 paper · 2019: 3 papers · 2020: 1 paper · 2021: none · 2022: none · 2023: 3 papers · 2024: 2 papers · 2025: 1 paper

Papers 24

  1. A phase 1 trial of APG-1387, an IAP antagonist, with nab-paclitaxel and gemcitabine in patients with refractory metastatic pancreatic cancer. Co-author DOI 10.1016/j.xcrm.2025.102364↗
  2. Ectopic CXCR2 expression cells improve the anti-tumor efficiency of CAR-T cells and remodel the immune microenvironment of pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s00262-024-03648-y↗
  3. Antigen/HLA-agnostic strategies for Characterizing Tumor-responsive T cell receptors in PDAC patients via single-cell sequencing and autologous organoid applic… Co-author DOI 10.1016/j.canlet.2024.216741↗
  4. Survival benefit of local consolidative therapy for patients with single-organ metastatic pancreatic cancer: a propensity score-matched cross-sectional study b… Co-author DOI 10.3389/fendo.2023.1225979↗
  5. Characterization of Estrogen Receptors in Pancreatic Adenocarcinoma with Tertiary Lymphoid Structures. Last author DOI 10.3390/cancers15030828↗
  6. Glutamine deprivation induces ferroptosis in pancreatic cancer cells. Co-author DOI 10.3724/abbs.2023029↗
  7. The role of survivin in the progression of pancreatic ductal adenocarcinoma (PDAC) and a novel survivin-targeted therapeutic for PDAC. Co-author DOI 10.1371/journal.pone.0226917↗
  8. PIK3CA in Kras G12D /Trp53 R172H Tumor Cells Promotes Immune Evasion by Limiting Infiltration of T Cells in a Model of Pancreatic Cancer Co-author DOI 10.1101/521831↗
  9. Tumor-intrinsic PIK3CA represses tumor immunogenecity in a model of pancreatic cancer. Co-author DOI 10.1172/jci123540↗
  10. Microfluidic Isolation of Circulating Tumor Cells and Cancer Stem-Like Cells from Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.7150/thno.28745↗
  11. A novel scoring system predicts postsurgical survival and adjuvant chemotherapeutic benefits in patients with pancreatic adenocarcinoma: Implications for AJCC-… Co-author DOI 10.1016/j.surg.2018.01.017↗
  12. Human Pancreatic Cancer Cells Induce a MyD88-Dependent Stromal Response to Promote a Tumor-Tolerant Immune Microenvironment. Co-author DOI 10.1158/0008-5472.can-16-1765↗
  13. Isolation of Pancreatic Cancer Cells from a Patient-Derived Xenograft Model Allows for Practical Expansion and Preserved Heterogeneity in Culture. Co-author DOI 10.1016/j.ajpath.2016.02.009↗
  14. ALDOA functions as an oncogene in the highly metastatic pancreatic cancer. Co-author DOI 10.1016/j.canlet.2016.01.054↗
  15. Nicotine Reduces Survival via Augmentation of Paracrine HGF-MET Signaling in the Pancreatic Cancer Microenvironment. Co-author DOI 10.1158/1078-0432.ccr-15-1256↗
  16. Downstream mediators of the intratumoral interferon response suppress antitumor immunity, induce gemcitabine resistance and associate with poor survival in hum… Co-author DOI 10.1007/s00262-015-1760-y↗
  17. Patient-derived xenograft models for pancreatic adenocarcinoma demonstrate retention of tumor morphology through incorporation of murine stromal elements. Co-author DOI 10.1016/j.ajpath.2015.01.016↗
  18. Epithelial-mesenchymal transition in pancreatic cancer: Is it a clinically significant factor? First author DOI 10.1016/j.bbcan.2014.11.004↗
  19. The inflammatory milieu within the pancreatic cancer microenvironment correlates with clinicopathologic parameters, chemoresistance and survival. Co-author DOI 10.1186/s12885-015-1820-x↗
  20. "Tissue is the issue": circulating tumor cells in pancreatic cancer. Last author DOI 10.1007/s12029-014-9638-3↗
  21. Abnormal distribution of peripheral lymphocyte subsets induced by PDAC modulates overall survival. Co-author DOI 10.1016/j.pan.2014.05.797↗
  22. Capture, release and culture of circulating tumor cells from pancreatic cancer patients using an enhanced mixing chip. Co-author DOI 10.1039/c3lc51017d↗
  23. Src inhibition is still a relevant target in pancreatic cancer. Last author DOI 10.1634/theoncologist.2013-0410↗
  24. microRNA signature for human pancreatic cancer invasion and metastasis. Co-author DOI 10.3892/etm.2012.585↗

Closest collaborators

The 25 strongest of 61 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xianjun Yu · 10 shared papers, 2012–2025 · strength 1.16
  2. Zhengjie Dai · 4 shared papers, 2023–2024 · strength 0.72
  3. He Cheng · 4 shared papers, 2015–2024 · strength 0.60
  4. Yesiboli Tasiheng · 3 shared papers, 2023–2024 · strength 0.55
  5. Mingjian Ma · 3 shared papers, 2023–2024 · strength 0.55
  6. Yusheng Chen · 3 shared papers, 2023–2024 · strength 0.55
  7. Xuan Lin · 3 shared papers, 2023–2024 · strength 0.55
  8. Xuan Zou · 3 shared papers, 2023–2024 · strength 0.55
  9. Thomas J. George · 9 shared papers, 2014–2019 · strength 0.52
  10. Kien Pham · 7 shared papers, 2015–2020 · strength 0.49
  11. Daniel Delitto · 7 shared papers, 2015–2020 · strength 0.39
  12. Jose Gilberto Trevino · 7 shared papers, 2014–2017 · strength 0.36
  13. Xu Wang · 2 shared papers, 2023–2024 · strength 0.36
  14. Si Shi · 4 shared papers, 2012–2025 · strength 0.32
  15. Ryan Michael Thomas · 6 shared papers, 2015–2017 · strength 0.29
  16. K.E. Behrns · 6 shared papers, 2015–2017 · strength 0.29
  17. Shannon Margaret Wallet · 6 shared papers, 2015–2017 · strength 0.29
  18. Steven J. Hughes · 6 shared papers, 2015–2017 · strength 0.29
  19. Quanxing Ni · 3 shared papers, 2016–2023 · strength 0.29
  20. Jin Xu · 5 shared papers, 2012–2018 · strength 0.24
  21. Z. Hugh Fan · 3 shared papers, 2014–2019 · strength 0.21
  22. Liang Liu · 4 shared papers, 2014–2018 · strength 0.20
  23. Miaoyan Wei · 1 shared paper, 2025 · strength 0.20
  24. Wei Wang · 1 shared paper, 2025 · strength 0.20
  25. Yifan Zhai · 1 shared paper, 2025 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.